ClinicaliQ Trial Snapshot
- A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight — Recruiting • Phase III • Diabetes / Metabolic • NCT07784270.
- Treatment being tested: AZD6234, a novel investigational agent, is being evaluated for its efficacy and safety in reducing body weight compared to placebo over 68 weeks in adults with type 2 diabetes who are overweight or obese.
- Patient eligibility: The trial includes adult participants with concurrent type 2 diabetes mellitus and either overweight or obesity, representing a population with significant comorbidity burden and treatment challenges.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Eligibility Snapshot
- : * Males & females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.